| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
GSK2850163 (S enantiomer) does not exhibit significant activity against IRE1α, as it is the inactive enantiomer of the compound. The active enantiomer of GSK2850163 targets IRE1α (inositol-requiring enzyme-1 alpha), a key sensor of the unfolded protein response (UPR) in the endoplasmic reticulum. By inhibiting IRE1α, the active compound modulates the UPR and downstream signaling pathways. The S enantiomer serves as a control to confirm that observed effects are due to specific IRE1α inhibition rather than off-target effects.
|
|---|---|
| ln Vitro |
In vitro, GSK2850163 (S enantiomer) is used as a negative control in cellular assays. Unlike the active enantiomer, the S enantiomer does not inhibit IRE1α activity or modulate the unfolded protein response. Its lack of activity makes it a valuable tool for validating the specificity of IRE1α inhibition by the active enantiomer and for distinguishing on-target from off-target effects in cellular studies.
|
| ln Vivo |
In vivo activity data for GSK2850163 (S enantiomer) are limited. As the inactive enantiomer, it is not expected to exhibit the IRE1α inhibitory activity of the active enantiomer. It may be used in animal studies as a negative control to confirm that the effects of the active enantiomer are due to specific IRE1α inhibition rather than off-target effects.
|
| Enzyme Assay |
For non-cellular in vitro assays, GSK2850163 (S enantiomer) is used as a negative control to validate the specificity of IRE1α inhibition. The compound is tested alongside the active enantiomer in enzyme assays using purified IRE1α. The lack of inhibitory activity of the S enantiomer confirms that the observed inhibition by the active enantiomer is due to specific IRE1α targeting.
|
| Cell Assay |
For in vitro cellular assays, GSK2850163 (S enantiomer) is used as a negative control in IRE1α signaling studies. Cells are treated with the S enantiomer alongside the active enantiomer, and IRE1α activity (XBP1 splicing, IRE1α phosphorylation) is measured. The lack of effect of the S enantiomer confirms that the effects of the active enantiomer are due to specific IRE1α inhibition.
|
| Animal Protocol |
For in vivo animal studies, GSK2850163 (S enantiomer) is used as a negative control to validate the specificity of IRE1α inhibition. Animals are treated with the S enantiomer alongside the active enantiomer, and IRE1α signaling and disease-related endpoints are assessed. The lack of effect of the S enantiomer confirms that the effects of the active enantiomer are due to specific IRE1α inhibition.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for GSK2850163 (S enantiomer) are limited. As the inactive enantiomer of GSK2850163, its pharmacokinetic properties are expected to be similar to those of the active enantiomer. Further pharmacokinetic studies would be needed to fully characterize its absorption, distribution, metabolism, and excretion profile. The compound is for research use only and not for human use.
|
| Toxicity/Toxicokinetics |
Toxicological data for GSK2850163 (S enantiomer) are limited. As the inactive enantiomer, it is not expected to exhibit the on-target toxicities associated with IRE1α inhibition. However, comprehensive toxicology studies would be required for therapeutic development of the active enantiomer. The compound is for research use only and not for human use.
|
| References | |
| Additional Infomation |
GSK2850163 (S enantiomer) is the inactive enantiomer of GSK2850163, an IRE1α inhibitor. It is used as a negative control in research studies to validate the specificity of IRE1α inhibition. The compound has a CAS number of 2309519-81-9. It is a valuable tool for distinguishing on-target IRE1α effects from off-target effects in cellular and animal studies.
|
| Molecular Formula |
C24H29CL2N3O
|
|---|---|
| Molecular Weight |
446.41
|
| Exact Mass |
445.168
|
| CAS # |
2309519-81-9
|
| Related CAS # |
GSK2850163;2121989-91-9
|
| PubChem CID |
132274059
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
4.9
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
30
|
| Complexity |
583
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CC1=CC=C(C=C1)CNC(=O)N2CCC[C@]3(C2)CCN(C3)CC4=CC(=C(C=C4)Cl)Cl
|
| InChi Key |
YFDASBFQKMHSSJ-DEOSSOPVSA-N
|
| InChi Code |
InChI=1S/C24H29Cl2N3O/c1-18-3-5-19(6-4-18)14-27-23(30)29-11-2-9-24(17-29)10-12-28(16-24)15-20-7-8-21(25)22(26)13-20/h3-8,13H,2,9-12,14-17H2,1H3,(H,27,30)/t24-/m0/s1
|
| Chemical Name |
(5S)-2-[(3,4-dichlorophenyl)methyl]-N-[(4-methylphenyl)methyl]-2,7-diazaspiro[4.5]decane-7-carboxamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2401 mL | 11.2005 mL | 22.4009 mL | |
| 5 mM | 0.4480 mL | 2.2401 mL | 4.4802 mL | |
| 10 mM | 0.2240 mL | 1.1200 mL | 2.2401 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
